Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study.
Acute Disease
Aged
Aged, 80 and over
Biomarkers
/ blood
Blood Glucose
/ drug effects
Diabetes Mellitus
/ blood
Female
Glycated Hemoglobin
/ metabolism
Heart Failure
/ diagnosis
Hospital Mortality
Humans
Hypoglycemic Agents
/ therapeutic use
Male
Middle Aged
Prognosis
Prospective Studies
Registries
Republic of Korea
/ epidemiology
Risk Assessment
Risk Factors
Stroke Volume
Time Factors
Ventricular Function, Left
Acute heart failure
Diabetes mellitus
Glycemic control
Left ventricular ejection fraction
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
02 05 2020
02 05 2020
Historique:
received:
10
02
2020
accepted:
25
04
2020
entrez:
4
5
2020
pubmed:
4
5
2020
medline:
26
8
2020
Statut:
epublish
Résumé
Although more than one-third of the patients with acute heart failure (AHF) have diabetes mellitus (DM), it is unclear if DM has an adverse impact on clinical outcomes. This study compared the outcomes in patients hospitalized for AHF stratified by DM and left ventricular ejection fraction (LVEF). The Korean Acute Heart Failure registry prospectively enrolled and followed 5625 patients from March 2011 to February 2019. The primary endpoints were in-hospital and overall all-cause mortality. We evaluated the impact of DM on these endpoints according to HF subtypes and glycemic control. During a median follow-up of 3.5 years, there were 235 (4.4%) in-hospital mortalities and 2500 (46.3%) overall mortalities. DM was significantly associated with increased overall mortality after adjusting for potential confounders (adjusted hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.03-1.22). In the subgroup analysis, DM was associated with higher a risk of overall mortality in heart failure with reduced ejection fraction (HFrEF) only (adjusted HR 1.14, 95% CI 1.02-1.27). Inadequate glycemic control (HbA1c ≥ 7.0% within 1 year after discharge) was significantly associated with a higher risk of overall mortality compared with adequate glycemic control (HbA1c < 7.0%) (44.0% vs. 36.8%, log-rank p = 0.016). DM is associated with a higher risk of overall mortality in AHF, especially HFrEF. Well-controlled diabetes (HbA1c < 7.0%) is associated with a lower risk of overall mortality compared to uncontrolled diabetes. Trial registration ClinicalTrial.gov, NCT01389843. Registered July 6, 2011. https://clinicaltrials.gov/ct2/show/NCT01389843.
Sections du résumé
BACKGROUND
Although more than one-third of the patients with acute heart failure (AHF) have diabetes mellitus (DM), it is unclear if DM has an adverse impact on clinical outcomes. This study compared the outcomes in patients hospitalized for AHF stratified by DM and left ventricular ejection fraction (LVEF).
METHODS
The Korean Acute Heart Failure registry prospectively enrolled and followed 5625 patients from March 2011 to February 2019. The primary endpoints were in-hospital and overall all-cause mortality. We evaluated the impact of DM on these endpoints according to HF subtypes and glycemic control.
RESULTS
During a median follow-up of 3.5 years, there were 235 (4.4%) in-hospital mortalities and 2500 (46.3%) overall mortalities. DM was significantly associated with increased overall mortality after adjusting for potential confounders (adjusted hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.03-1.22). In the subgroup analysis, DM was associated with higher a risk of overall mortality in heart failure with reduced ejection fraction (HFrEF) only (adjusted HR 1.14, 95% CI 1.02-1.27). Inadequate glycemic control (HbA1c ≥ 7.0% within 1 year after discharge) was significantly associated with a higher risk of overall mortality compared with adequate glycemic control (HbA1c < 7.0%) (44.0% vs. 36.8%, log-rank p = 0.016).
CONCLUSIONS
DM is associated with a higher risk of overall mortality in AHF, especially HFrEF. Well-controlled diabetes (HbA1c < 7.0%) is associated with a lower risk of overall mortality compared to uncontrolled diabetes. Trial registration ClinicalTrial.gov, NCT01389843. Registered July 6, 2011. https://clinicaltrials.gov/ct2/show/NCT01389843.
Identifiants
pubmed: 32359358
doi: 10.1186/s12933-020-01026-3
pii: 10.1186/s12933-020-01026-3
pmc: PMC7196232
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
hemoglobin A1c protein, human
0
Banques de données
ClinicalTrials.gov
['NCT01389843']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Références
J Am Coll Cardiol. 2004 Mar 3;43(5):771-7
pubmed: 14998615
J Am Coll Cardiol. 2013 Mar 26;61(12):1259-67
pubmed: 23500328
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1081-1091
pubmed: 30318112
JACC Heart Fail. 2017 Nov;5(11):763-771
pubmed: 29032140
Circ Heart Fail. 2014 Jan;7(1):76-87
pubmed: 24281134
Eur Heart J. 2008 Jun;29(11):1377-85
pubmed: 18413309
Circ Heart Fail. 2008 Nov;1(4):234-41
pubmed: 19808297
Am Heart J. 2014 Nov;168(5):721-30
pubmed: 25440801
J Am Coll Cardiol. 2007 Aug 21;50(8):768-77
pubmed: 17707182
Cardiovasc Diabetol. 2019 Jul 5;18(1):86
pubmed: 31277657
Diabetes Care. 2004 Aug;27(8):1879-84
pubmed: 15277411
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
J Am Coll Cardiol. 2013 Jan 29;61(4):391-403
pubmed: 23219302
Cardiovasc Diabetol. 2019 Sep 3;18(1):116
pubmed: 31481069
Int J Cardiol. 2016 Jan 15;203:587-93
pubmed: 26574932
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
Circulation. 2011 Sep 6;124(10):1151-9
pubmed: 21844073
J Clin Invest. 2010 May;120(5):1506-14
pubmed: 20407209
J Am Coll Cardiol. 2013 Feb 26;61(8):820-9
pubmed: 23333145
Cell Metab. 2012 May 2;15(5):635-45
pubmed: 22560216
Eur Heart J. 2006 Nov;27(22):2725-36
pubmed: 17000631
Eur J Heart Fail. 2017 Oct;19(10):1258-1269
pubmed: 28370829
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2014 Jan;16(1):103-11
pubmed: 24453099
JACC Heart Fail. 2015 Feb;3(2):136-45
pubmed: 25660838
Rev Esp Cardiol (Engl Ed). 2019 Oct 16;:
pubmed: 31629690
Circulation. 2009 Apr 14;119(14):1899-907
pubmed: 19332465
Eur Heart J. 2014 Mar;35(10):657-64
pubmed: 23756336
Am Heart J. 2007 Aug;154(2):277.e1-8
pubmed: 17643576
Int J Cardiol. 2012 May 17;157(1):108-13
pubmed: 22178056
Circulation. 2017 Feb 21;135(8):724-735
pubmed: 28052977
Eur J Heart Fail. 2017 Dec;19(12):1586-1596
pubmed: 28295985
Cardiovasc Diabetol. 2003 Jan 08;2:1
pubmed: 12556246
Korean Circ J. 2017 May;47(3):341-353
pubmed: 28567084
JACC Heart Fail. 2020 Mar;8(3):234-242
pubmed: 32035890
Eur J Heart Fail. 2017 Jan;19(1):54-65
pubmed: 27790816
Cardiovasc Diabetol. 2019 Apr 8;18(1):47
pubmed: 30961600
Eur J Heart Fail. 2013 Feb;15(2):194-202
pubmed: 23059198
Eur Heart J. 2004 Apr;25(8):656-62
pubmed: 15084370
Eur J Heart Fail. 2014 Jun;16(6):700-8
pubmed: 24797348